.Competing rate of interests.R.S., M.S., H.G. and also A.A.R. are organizers of the 1M1M project. H.G. and also A.A.R. are actually panel of directors participants and R.S., M.S. and also A.A.R. are actually members of the clinical advisory committee of N1C. A.A.R. reveals work through LUMC, which has licenses on exon-skipping modern technology, some of which has been actually certified to BioMarin as well as ultimately sublicensed to Sarepta. As co-inventor of a few of these licenses, A.A.R. was qualified to a share of royalties. A.A.R. further makes known functioning as consultant for PTC Rehabs, Sarepta Therapeutics, Regenxbio, Dyne Therapies, Lilly, BioMarin Pharmaceuticals Inc., Eisai, Entrada, Takeda, Splicesense, Galapagos, Sapreme, Italfarmaco and Astra Zeneca. Over the last 5 years, A.A.R. also performed impromptu seeking advice from for Alpha Anomeric. A.A.R. also mentions registration of the clinical advisory boards of Eisai, Hybridize Rehabs, Silence Therapies, Sarepta Therapies, Sapreme and Mitorx. In the past 5 years, A.A.R. was also a medical board of advisers member for ProQR. Commission for A.A.R. u00e2 s consulting and encouraging tasks is spent to LUMC. Before 5 years, LUMC also received speaker honoraria from PTC Therapeutics, Alnylam Netherlands, Italfarmaco and also Pfizer as well as funding for agreement analysis coming from Sapreme, Eisai, Galapagos, Synaffix as well as Alpha Anomeric. Task funding is actually gotten coming from Sarepta Therapeutics and also Entrada via unconstrained gives. H.G. possesses nothing to disclose relative to the subject matters dealt with in this composition. In the past 5 years, he has actually additionally received consultancy honoraria from UCB. M.S. obtained consultancy honoraria from Ionis, UCB, Prevail, Orphazyme, Biogen, Servier, Reata, GenOrph, AviadoBio, Biohaven, Zevra, Lilly as well as Solaxa previously 5 years, all unrelated to the here and now document. R.S. has nothing to make known relative to the topics dealt with in this particular manuscript. She has received sound speaker and/or working as a consultant honoraria or funding contributions coming from Abbvie, Bial, STADA and also Everpharma previously 5 years.